MillerP.H., PurcellR.H.. Hepatitis C virus shares aminoacid sequence similarity with pestiviruses and flaviviruses as well as members of two plant virus supergroups. Proc Natl Acad Sci1990; 87: 2050–61.
2.
ChooQ.L., KuoG., WeinerA.J., OverbyL.R., BradleyD.W., HoughtonM.. Isolation of a cDNAclone derived from a blood-borne non-A, non-B viral hepatitis genome. Science1989; 244: 359–62.
3.
AlterH.J., PurcellR.H., ShihS.W.Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med1989; 321: 1494–500.
4.
AlterM.J., MargolisH.S., KrawczynskiK., JudsonF.N., MaresA., AlexanderW.J., HuP.Y.H., MillerJ.K., GerberM.A., SamplinerR.E., MeeksE.L., BeachM.J., for the Sentinel Counties Chronic Non-A, Non-B Hepatitis Study Team. The natural history of community-acquired hepatitis C in the United States. N Engl J Med1992; 327: 1899–905.
5.
Stehman-BreenC.O., EmersonS., GretchD., JohnsonR.J.. Risk of death among chronic dialysis patients infected with hepatitis C virus. Am J Kidney Dis1998; 32: 629–34.
6.
NakayamaE., AkibaT., MarumoF., SatoC.. Prognosis of anti-hepatitis C virus antibody-positive patients on regular hemodialysis therapy. J Am Soc Nephrol2000; 11: 1896–902.
7.
MaisonneuveP., AgodoaL., GeliertR.Cancer in patients on dialysis for end-stage renal disease: an international collaborative study. Lancet1999; 354: 93–9.
8.
EspinosaM., Martin-MaloA., de LaraM.A.M., AlijamaP.. Risk of death and liver cirrhosis in anti-HCV positive long-term haemodialysis patients. Nephrol Dial Transplant2001; 16: 1669–74.
9.
MarcelliD., StanhardD., ConteF., HeldP.J., LocatelliF., PortF.K.. ESRD patient mortality with adjustment for comorbid conditions in Lombardy (Italy) versus the United States. Kidney Int1996; 50: 1013–8.
10.
WestonS.R., MartinP.. Serological and molecular testing in viral hepatitis: An update. Can J Gastroenterol2001; 15: 177–84.
11.
Centers for Disease Control and Prevention.Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR1998; 47(RR-19): 1–39.
12.
FabriziF., Di FilippoS., ErbaG.Hepatitis C virus infection and hepatic function in chronic hemodialysis patients. Nephron1992; 61: 119 (letter).
13.
GetzugT., LindsayK., BrezinaM., GitnickG.. Hepatitis C virus antibody in hemodialysis patients. Prevalence and risk factors. Lancet1990; 335: 589 (letter).
14.
ZeldisJ.B., DepnerT.A., KuramotoI.K., GishR.G., HollandP.V.. The prevalence of hepatitis C virus antibodies among hemodialysis patients. Ann Intern Med1990; 112: 958–60.
15.
MondelliM.U., SmedileV., PiazzaV.Abnormal alanine aminotransferase activity reflects exposure to hepatitis C virus in hemodialysis patients. Nephrol Dial Transplant1991; 6: 480–3.
16.
LinH.H., HuangC.C., SheenI.S., LinD.Y., LiawY.F.. Prevalence of antibodies to hepatitis C virus in the hemodialysis unit. Am J Nephrol1991; 11: 192–4.
17.
CarreraF., SilvaJ.G., PiresC., OliveiraC.. Prevalence of non-A, non-B hepatitis and anti-HCV antibodies in a Portoguese dialysis population. Nephrol Dial Transplant1992; 7: 913–6.
18.
GilliP., MorettiM., SoffrittiS.Non-A, non-B hepatitis and anti-HCV antibodies in dialysis patients. Int J Artif Organs1990; 13: 737–41.
19.
AlonsoM.C., NovoaD., RomeroR., ArcochaV., Sanchez-GuisandeD.. Antibodies to hepatitis C virus in patients on haemodialysis. Nephron1991; 57: 247 (letter).
20.
HardyN.M., SandroniS., DanielsonS., WilsonD.J.. Antibody to hepatitis C virus increases with time on hemodialysis. Clin Nephrol1992; 38: 44–8.
21.
LinD.Y., LinH.H., HuangC.C., LiawY.F.. High incidence of hepatitis C virus infection in hemodialysis patients. Am J Kidney Dis1993; 21: 288–291.
22.
SheuJ.C., LeeS.H., WangJ.T., ShihL.N., WangT.H., ChenD.S.. Prevalence of anti-HCV and HCV viremia in hemodialysis patients in Taiwan. J Med Virol1992; 37: 108–12.
23.
NiuM.T., ColemanP.J., AlterM.J.. Multicenter study of hepatitis C virus infection in chronic hemodialysis patients and hemodialysis center staff members. Am J Kidney Dis1993; 22: 568–73.
24.
FabriziF., ErbaG.F., Di FilippoS.Antibodies to hepatitis C virus and transaminase concentration in chronic haemodialysis patients: a study with second-generation assays. Nephrol Dial Transplant1993; 8: 744–7.
25.
MondelliM.U., CristinaG., PiazzaV., CerinoA., VillaG., SalvadeoA.. High prevalence of antibodies to hepatitis C virus in hemodialysis units using a second-generation assay. Nephron1992; 61: 350–1.
26.
VitaleC., TricerriA., MarangellaM.Epidemiology of hepatitis C virus infection in dialysis units: first- versus second-generation assays. Nephron1993; 64: 315–6.
27.
BlackmoreT.K., MaddocksP., StawN.H., HatfieldP.. Prevalence of antibodies to hepatitis C virus in patients receiving renal replacement therapy and in the staff caring to them. Aust NZ J Med1992; 22: 352–7.
FabriziF., RaffaeleL., GuarnoriI.Comparison of second-generation screening and confirmatory assays with recombinant antigens and synthetic peptides against antibodies to hepatitis C virus: a study in renal patients. Nephron1995; 69: 444–8.
30.
BeldM., PenningM., van PuttenM.Quantitative antibody responses to structural (core) and nonstructural (NS3, NS4, and NS5) hepatitis C virus proteins among seroconverting injecting drug users: impact of epitope variation and relationship to detection of HCV RNA in blood. Hepatology1999; 29: 1288–98.
31.
FabriziF., LunghiG., RaffaeleL.Serologic survey for control of hepatitis C in haemodialysis patients: third-generation assays and analysis of costs. Nephrol Dial Transplant1997; 12: 298–303.
32.
CouroucèA.M., BouchardeauF., ChauveauP.Hepatitis C virus (HCV) infection in haemodialysed patients: HCV RNA and anti-HCV antibodies (third-generation assays). Nephrol Dial Transplant1995; 10: 234–9.
33.
van der PoelC.L., CuypersH.T., ReesinkH.W.Confirmation of hepatitis C virus infection by new four antigen recombinant immunoblot assay. Lancet1991; 337: 317–9.
34.
UyttendaeleS., ClaeysH., MertensW., VerhaertH., VermylenC.. Evaluation of third-generation screening and confirmatory assays for HCV antibodies. Vox Sang1994; 66: 122–9.
HennogH., KirchnerH., KluterH.. Failure of third-generation recombinant immunoblot assay to detect hepatitis C virus core antibodies. Transfusion1999; 39: 335–36.
37.
PawlotskyJ.M., LonjonI., HezodeC.What strategy should be used for diagnosis of hepatitis C virus infection in clinical laboratories?Hepatology1998; 27: 1700–2.
38.
AI MeshariK., AI AhdalM., AlfurayhO., AliA., De VolE., KessieG.. New insights into hepatitis C virus infection of hemodialysis patients: the implications. Am J Kidney Dis1995; 25: 572–8.
39.
DixitV., QuanS., MartinP.Evaluation of a novel serotyping system for hepatitis C virus: Strong correlation with standard genotyping methodologies. J Clin Microbiol1995; 33: 2978–83.
FabriziF., MartinP., DixitV.Automated RIBA™ HCV Strip Immunoblot Assay: a novel tool for the diagnosis of hepatitis C virus infection in hemodialysis patients. Am J Nephrol2001; 21: 104–11.
42.
TaboneM., SecretoP., MariniC.Pre-treatment levels of anti-HCV core IgM antibodies are closely associated with response to alpha interferon therapy in chronic hepatitis C patients. J Gastroenterol Hepatol1997; 9: 287–91.
43.
FabriziF., LunghiG., GuarnoriI.IgM antibody response to hepatitis C virus in end-stage renal disease. Nephrol Dial Transplant1996; 11: 314–8.
44.
Centers for Disease Control and Prevention.Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR2001; 50(RR-S): 1–43.
45.
SaldanhaJ., LelieN., HealthA.. Establishment of the first international standard for nucleic acid amplification technology (NAT) assays for HCV RNA. WHO Collaborative Study Group. Vox Sang1999; 76: 149–58.
46.
DogliaA., LaffontC., Carolo-BoscF.X., RochetP., LeFebvreJ.C.. Second generation of the automated cobas amplicor HCV assay improves sensitivity of hepatitis C virus RNA. J Clin Microbiol1999; 37: 1567–9.
47.
PawlotskyJ.M.. Measuring hepatitis C viremia in clinical samples: can we trust the assays?Hepatology1997; 26: 1–4.
48.
BukhJ., WantzinP., KrogsgaardK., KnudsenF., PurcellR.H., MillerR.H., and The Copenhagen Dialysis HCV Study Group. High prevalence of hepatitis C virus (HCV) RNA in dialysis patients: failure of commercially available antibody tests to identify a significant number of patients with HCV infection. J Infect Dis1993; 168: 1343–8.
49.
FernandezJ.L., Del PinoN., LefL.Serum hepatitis C virus RNA in anti-HCV negative hemodialysis patients. Dial Transplant1996; 25: 14–8.
50.
FabriziF., MartinP., DixitV.Quantitative assessment of HCV load in chronic hemodialysis patients: a cross-sectional survey. Nephron1998; 80: 428–33.
51.
DalekosG.N., BoumbaD.S., KatopodisK.Absence of HCV viraemia in anti-HCV negative haemodialysis patients. Nephrol Dial Transplant1998; 13: 1804–6.
52.
FabriziF., MartinP., DixitV.Acquisition of hepatitis C virus in hemodialysis patients: a prospective study by branched DNA signal amplification assay. Am J Kidney Dis1998; 31: 647–54.
53.
FabriziF., MartinP., DixitV.Biologycal dynamics of viral load in hemodialysis patients with hepatitis C virus. Am J Kidney Dis2000; 35: 122–9.
54.
TongM.J., BlattL.M., McHutchisonJ.G., CoR.L., ConradA.. Prediction of response during interferon alfa 2b therapy in chronic hepatitis C patients using viral and biochemical characteristics: a comparison. Hepatology1997; 26: 1640–5.
55.
DuBoisD.B., GretchD., dela RosaC., LeeW., FineJ., BlaggC.R., CoreyL.. Quantification of hepatitis C viral RNAin sera of hemodialysis patients: gender-related differences in viral load. Am J Kidney Dis1994; 24: 795–801.
56.
FurusyoN., HayashiJ., AriyamaI.Maintenance hemodialysis decreases serum hepatitis C virus (HCV) RNA levels in hemodialysis patients with chronic HCV infection. Am J Gastroenterol2000; 95: 490–6.
57.
DavisG.L., LauJ.Y.N.. Factors predictive of a beneficial response to therapy of hepatitis C. Hepatology1997; 26: S122–7.
58.
GishR.G.. Future directions in the treatment of patients with chronic hepatitis C viral infection. Can J Gastroenterol1999; 13: 57–62.
59.
CiveiraM.P., PrietoJ.. Early predictors of response to treatment in patients with chronic hepatitis C. J Hepatol1999; 31: 237–43.
60.
TakeuchiT., KatsumeA., TanakaT.Real-time detection system for quantification of hepatitis C virus genome. Gastroenterology1999; 116: 636–42.
61.
MartellM., GomezJ., EstebanJ.L.High-throughput real-time reverse transcription-PCR quantitation of hepatitis C virus RNA. J Clin Microbiol1999; 37: 327–32.
62.
MercierB., BurlotL., FerecC.. Simultaneous screening for HBV DNA and HCV RNA genomes in blood donations using a novel TaqMan PCR assay. J Virol Methods1999; 77: 1–9.
63.
SimmondsP., AlbertiA., AlterH.J.A proposed system for nomenclature of hepatitis C viral genomes. Hepatology1994; 19: 1321–4.
64.
PolS., ThiersV., NousbaumJ.B., LegendreC., BerthelotP., KreisH., BrechotC.. The changing relative prevalence of hepatitis C virus genotypes: evidence in hemodialyzed patients and kidney recipients. Gastroenterology1995; 108: 581–3.
65.
ChouW.H., LinS.F., SheuS.H., LuC.F., LinS.Y., WuJ.S.. Comparisons of hepatitis C virus strains obtained from hemodialysis patients. Jpn J Med Sci Biol1993; 46: 191–202.
66.
FabriziF., LunghiG., GuarnoriI., RaffaeleL., PaganoA., LocatelliF.. Hepatitis C virus genotypes in chronic dialysis patients. Nephrol Dial Transplant1996; 11: 679–83.
67.
FabriziF., LunghiG., PagliariB., ManganoS., FarannaP., PaganoA., LocatelliF.. Molecular epidemiology of hepatitis C virus infection in dialysis patients. Nephron1997; 77: 190–6.
68.
BosmansJ.L., NouwenE.J., BehetsG., GortemanK., HuraibS.O., ShaheenF.A., MaertensG., VerpootenG.A., ElseviersM.M., De BroeM.E., and the collaborating centers from Belgium and Saudi-Arabia. Prevalence and clinical expression of HCV-genotypes in haemodialysis patients of two geographically remote countries: Belgium and Saudi Arabia. Clin Nephrol1997; 47: 256–62.
69.
GoessensC., JadoulM., WalonC., BurtonboyG., CornuC.. Hepatitis C virus genotypes in hemodialyzed patients: a multicentre study. Clin Nephrol1997; 47: 367–71.
70.
OkamotoH., SugiyamaY., OkadaS.Typing hepatitis C virus by polymerase chain reaction with type-specific primers: Application to clinical surveys and tracing infectious sources. J Gen Virol1992; 73: 673–9.
71.
TakadaN., TakaseS., EnomotoN., TakadaA., DateT.. Clinical background of the patients having different types of hepatitis C virus genomes. J Hepatol1992; 14: 35–40.
72.
NakaoT., EnomotoN., TakedaA., DateT.. Typing of hepatitis C virus genomes by restriction fragment length polymorphism. J Gen Virol1991; 72: 2105–12.
73.
RavaggiA., ZonaroA., MarinM.G., PuotiM., AlbertiniA., CarianiE.. Distribution of viral genotypes in Italy determined by hepatitis C virus typing by DNA immunoassay. J Clin Microbiol1994; 32: 2280–4.
74.
StuyverL., RossauR., WyseurA., DuhamelM., VanderboghtB., van HeuverswynH., MaertensG.. Typing of HCV isolates and characterization of new subtypes using a line probe assay. J Gen Virol1993; 74: 1093–102.
75.
SimmondsP., RoseK.A., GrahamS.Mapping of serotype-specific, immunodominant epitopes in the NS-4 region of hepatitis C virus (HCV): use of type-specific peptides to serologically differentiate infections with HCV types 1, 2 and 3. J Clin Microbiol1993; 31: 1493–503.
76.
FabriziF., MartinP., QuanS.RIBA™ HCV serotyping Strip Immunoblot Assay (SIA) for assessing hepatitis C virus (HCV) strains in dialysis patients: strong association with genotyping technology. Am J Kidney Dis2000; 35: 832–8.
77.
TakadaA., TsutsumiM., ZhangS.C.Relationship between hepatocellular carcinoma and subtypes of hepatitis C virus: a nationwide analysis. J Gastroenterol Hepatol1996; 11: 166–9.
78.
MurakamiC., HinoK., KorenagaM.Factors predicting progression to cirrhosis and hepatocellular carcinoma in patients with transfusion-associated hepatitis C virus infection. J Clin Gastroenterol1999; 28: 148–52.
79.
MartinP.. Hepatitis C genotypes: The key to pathogenicity?Ann Intern Med1995; 122: 227–8.
80.
ZhouS., TerraultN.A., FerrellL.Severity of liver disease in liver transplant recipients with hepatitis C virus infection: relationship to genotypes and level of viremia. Hepatology1996; 24: 1041–6.
81.
McHutchisonJ.G., GordonS.C., SchiffE.R.. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med1999; 339: 1485–92.
82.
MannsM.P., McHutchisonJ.G., GordonS.C., RustgiV.K., ShiffmanM., ReindollarR., GoodmanZ.D., KouryK., LingM.H., AlbrechtJ.K., and The International Hepatitis Interventional Therapy Group. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet2001; 368: 958–65.
